News Home

Day One Biopharmaceuticals Inc (DAWN) is lower by -6.51% in a Week, Should You Accumulate?

Friday, May 26, 2023 03:15 PM | InvestorsObserver Analysts

Mentioned in this article

Day One Biopharmaceuticals Inc (DAWN) is lower by -6.51% in a Week, Should You Accumulate?

Day One Biopharmaceuticals Inc (DAWN) is near the top in its industry group according to InvestorsObserver. DAWN gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Day One Biopharmaceuticals Inc gets a 72 rank in the Biotechnology industry. Biotechnology is number 22 out of 148 industries.

Overall Score - 66
DAWN has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on DAWN!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Day One Biopharmaceuticals Inc Stock Today?

Day One Biopharmaceuticals Inc (DAWN) stock is trading at $12.49 as of 3:15 PM on Friday, May 26, a rise of $0.43, or 3.57% from the previous closing price of $12.06. The stock has traded between $12.00 and $12.53 so far today. Volume today is light. So far 635,567 shares have traded compared to average volume of 910,060 shares. Click Here to get the full Stock Report for Day One Biopharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App